Abstract
Familial hypercholesterolaemia is a relatively frequently occurring disease that is strongly associated with vascular disease. Current treatment with cholesterol-lowering agents is partly effective but shows variable responses between patients with familial hypercholesterolaemia. Recently, new cholesterol-lowering drugs have been developed. Here we describe the most promising of these new agents for which results from phase 2 or phase 3 trials are available. We will discuss the data regarding lipid-lowering potential and safety issues and speculate about the potential reductions of the residual risk of statin-treated FH patients.
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 227-233 |
| Number of pages | 7 |
| Journal | Netherlands Journal of Medicine |
| Volume | 71 |
| Issue number | 5 |
| Publication status | Published - 2013 |
Research programs
- EMC COEUR-09